Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

How We Treat Recurrent Glioblastoma Today and Current Evidence.

Chaul-Barbosa C, Marques DF.

Curr Oncol Rep. 2019 Oct 12;21(10):94. doi: 10.1007/s11912-019-0834-y. Review.

PMID:
31606796
2.

Anti-angiogenic therapy for high-grade glioma.

Ameratunga M, Pavlakis N, Wheeler H, Grant R, Simes J, Khasraw M.

Cochrane Database Syst Rev. 2018 Nov 22;11:CD008218. doi: 10.1002/14651858.CD008218.pub4.

PMID:
30480778
3.

Systemic treatments for metastatic cutaneous melanoma.

Pasquali S, Hadjinicolaou AV, Chiarion Sileni V, Rossi CR, Mocellin S.

Cochrane Database Syst Rev. 2018 Feb 6;2:CD011123. doi: 10.1002/14651858.CD011123.pub2. Review.

4.
5.

Re-irradiation after gross total resection of recurrent glioblastoma : Spatial pattern of recurrence and a review of the literature as a basis for target volume definition.

Straube C, Elpula G, Gempt J, Gerhardt J, Bette S, Zimmer C, Schmidt-Graf F, Meyer B, Combs SE.

Strahlenther Onkol. 2017 Nov;193(11):897-909. doi: 10.1007/s00066-017-1161-6. Epub 2017 Jun 14.

PMID:
28616821
6.

Bevacizumab for the treatment of high-grade glioma: an update after phase III trials.

Khasraw M, Ameratunga M, Grommes C.

Expert Opin Biol Ther. 2014 May;14(5):729-40. doi: 10.1517/14712598.2014.898060. Epub 2014 Mar 22. Review.

PMID:
24655021
7.

Antiangiogenic therapy for high-grade glioma.

Khasraw M, Ameratunga MS, Grant R, Wheeler H, Pavlakis N.

Cochrane Database Syst Rev. 2014 Sep 22;(9):CD008218. doi: 10.1002/14651858.CD008218.pub3. Review. Update in: Cochrane Database Syst Rev. 2018 Nov 22;11:CD008218.

PMID:
25242542
8.

Triple-drug Therapy With Bevacizumab, Irinotecan, and Temozolomide Plus Tumor Treating Fields for Recurrent Glioblastoma: A Retrospective Study.

Lu G, Rao M, Zhu P, Liang B, El-Nazer RT, Fonkem E, Bhattacharjee MB, Zhu JJ.

Front Neurol. 2019 Jan 31;10:42. doi: 10.3389/fneur.2019.00042. eCollection 2019.

9.

Bevacizumab in Recurrent High-Grade Gliomas: A Canadian Retrospective Study.

Lim Fat MJ, Maurice C, Maganti M, Mason WP.

Can J Neurol Sci. 2018 Jan;45(1):56-61. doi: 10.1017/cjn.2017.248. Epub 2017 Nov 20.

PMID:
29151389
10.

The Role of Checkpoint Inhibitors in Glioblastoma.

Desai K, Hubben A, Ahluwalia M.

Target Oncol. 2019 Aug;14(4):375-394. doi: 10.1007/s11523-019-00655-3. Review.

PMID:
31290002
11.

From a Patient Advocate's Perspective: Does Cancer Immunotherapy Represent a Paradigm Shift?

Madden DL.

Curr Oncol Rep. 2018 Feb 7;20(1):8. doi: 10.1007/s11912-018-0662-5. Review.

PMID:
29411148
12.

Clinical outcomes following salvage Gamma Knife radiosurgery for recurrent glioblastoma.

Larson EW, Peterson HE, Lamoreaux WT, MacKay AR, Fairbanks RK, Call JA, Carlson JD, Ling BC, Demakas JJ, Cooke BS, Lee CM.

World J Clin Oncol. 2014 May 10;5(2):142-8. doi: 10.5306/wjco.v5.i2.142. Review.

13.

New Approaches for Immune Directed Treatment for Ovarian Cancer.

Hardwick N, Frankel PH, Cristea M.

Curr Treat Options Oncol. 2016 Mar;17(3):14. doi: 10.1007/s11864-016-0389-1. Review.

PMID:
26942589
14.
15.

Phase I Trial of Radiosurgery Dose Escalation Plus Bevacizumab in Patients With Recurrent/Progressive Glioblastoma.

Abbassy M, Missios S, Barnett GH, Brewer C, Peereboom DM, Ahluwalia M, Neyman G, Chao ST, Suh JH, Vogelbaum MA.

Neurosurgery. 2018 Sep 1;83(3):385-392. doi: 10.1093/neuros/nyx369.

PMID:
28973311
16.

Clinical Trials Investigating Immune Checkpoint Blockade in Glioblastoma.

Maxwell R, Jackson CM, Lim M.

Curr Treat Options Oncol. 2017 Aug;18(8):51. doi: 10.1007/s11864-017-0492-y. Review.

PMID:
28785997
17.

Recent Advances in Oncolytic Virotherapy and Immunotherapy for Glioblastoma: A Glimmer of Hope in the Search for an Effective Therapy?

Stepanenko AA, Chekhonin VP.

Cancers (Basel). 2018 Dec 5;10(12). pii: E492. doi: 10.3390/cancers10120492. Review.

18.

Pharmacotherapy of Glioblastoma: Established Treatments and Emerging Concepts.

Franceschi E, Minichillo S, Brandes AA.

CNS Drugs. 2017 Aug;31(8):675-684. doi: 10.1007/s40263-017-0454-8. Review.

PMID:
28681349
19.

Immune Checkpoint in Glioblastoma: Promising and Challenging.

Huang J, Liu F, Liu Z, Tang H, Wu H, Gong Q, Chen J.

Front Pharmacol. 2017 May 9;8:242. doi: 10.3389/fphar.2017.00242. eCollection 2017. Review.

20.

Ipilimumab and Bevacizumab in Glioblastoma.

Carter T, Shaw H, Cohn-Brown D, Chester K, Mulholland P.

Clin Oncol (R Coll Radiol). 2016 Oct;28(10):622-6. doi: 10.1016/j.clon.2016.04.042. Epub 2016 May 8.

Supplemental Content

Support Center